Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Summary Studying mechanisms of malignant transformation of human pre-B cells, we found that acute activation of oncogenes induced immediate cell death in the vast majority of cells. Few surviving pre-B cell clones had acquired permissiveness to oncogenic signaling by strong activation of negative feedback regulation of Erk signaling. Studying negative feedback regulation of Erk in genetic experiments at three different levels, we found that Spry2, Dusp6 and Etv5 were essential for oncogenic transformation in mouse models for pre-B acute lymphoblastic leukemia (ALL). Interestingly, a small molecule inhibitor of DUSP6 selectively induced cell death in patient-derived pre-B ALL cells and overcame conventional mechanisms of drug-resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 2×
“In a wide range of solid tumors, acute hyperactivation of oncogenes including BRAF, Ras, and Myc can cause oncogene-induced senescence (Serrano et al., 1997; Michaloglou et al., 2005), which represents an important barrier against malignant transformation.”
BackgroundDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160 · cited 1×
“In a wide range of solid tumors, acute hyperactivation of oncogenes including BRAFV600E, Ras, and Myc can cause oncogene-induced senescence (Serrano et al., 1997; Michaloglou et al., 2005), which represents an important barrier against malignant transformation.”
BackgroundBCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072
A conserved docking motif in MAP kinases common to substrates, activators and regulators
Tanoue, T., Adachi, M., Moriguchi, T., & Nishida, E. (2000) · Nature Cell Biology · doi:10.1038/35000065 · Cited by 816
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · cited 1×
“Activated Erk translocates to the nucleus and drives transcriptional activation of proliferation via FOS, JUN, and MYC as well as its own negative feedback at three levels: (1) The sprouty family signaling inhibitor SPRY2 negatively regulates activation of RAS (Hanafusa et al., 2002).”
BackgroundA negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501 · cited 8×
“In multiple tumor types, DUSP6mediated feedback inhibition of Erk induces cellular senescence and represents a barrier against RAS-driven malignant transformation (Courtois-Cox et al., 2006).”
BackgroundResultInfluentialSprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Shaw, A. T., Meissner, A., Dowdle, J. A., Crowley, D., Magendantz, M., Ouyang, C., Parisi, T., Rajagopal, J., Blank, L. J., Bronson, R. T., et al. (2007) · Genes & Development · doi:10.1101/gad.1526207 · Cited by 131 · cited 2×
“Recent studies found that negative feedback regulators of Erk (DUSP6, ETV5, and SPRY2) are frequently inactivated in solid tumors (Xu et al., 2005; Shaw et al., 2007; Schutzman andMartin, 2012; Wong et al., 2012) and mature B cell lymphoma (Frank et al., 2009) and have an important role as tumor…”
Background
Cited by
A model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
Fighting Drug Resistance through the Targeting of Drug-Tolerant Persister Cells
De Conti, G., Dias, M. H., & Bernards, R. (2021) · Cancers · doi:10.3390/cancers13051118 · Cited by 111
“Interestingly, patientderived drug-resistant B-ALL cells showed increased sensitivity to DUSP6 inhibition [92].”
BackgroundMeeusen, B., & Janssens, V. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2017.10.002 · Cited by 96
“Moreover, knockdown of DUSP6 resulted in a decreased proliferation of the papillary cancer cell line TPC1 and the breast cancer cell line MDA-MB-231 (519, 520), whereas pharmacologic inhibition of DUSP6 induced cell death in patient-derived pre-B ALL cells (521).”
Background
Metadata
- Authors
- Shojaee, S., Caeser, R., Buchner, M., Park, E., Swaminathan, S., Hurtz, C., Geng, H., Chan, L. N., Klemm, L., Hofmann, W.-K., Qiu, Y. H., Zhang, N., Coombes, K. R., Paietta, E., Molkentin, J., Koeffler, H. P., Willman, C. L., Hunger, S. P., Melnick, A., Kornblau, S. M., & Müschen, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2015-07
- Volume
- 28
- Issue
- 1
- Pages
- 114-128
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W1916983144
- Cited by
- 138
- References
- 8
- FWCI
- 13.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.